The poor efficacy of the in vivo anti-tumor immune response has been partially attributed to ineffective T-cell responses mounted against the tumor. Fas-FasL-dependent activation-induced cell death (AICD) of T cells is believed to be a major contributor to compromised anti-tumor immunity. The molecular mechanisms of AICD are well-investigated, yet the possibility of regulating AICD for cancer therapy remains to be explored. In this study, we show that histone deacetylase inhibitors (HDACIs) can inhibit apoptosis of CD4 + T cells within the tumor, thereby enhancing anti-tumor immune responses and suppressing melanoma growth. This inhibitory effect is specific for AICD through suppressing NFAT1-regulated FasL expression on activated CD4 + T cells. In gld/gld mice with mutation in FasL, the beneficial effect of HDACIs on AICD of infiltrating CD4 + T cells is not seen, confirming the critical role of FasL regulation in the anti-tumor effect of HDACIs. Importantly, we found that the co-administration of HDACIs and anti-CTLA4 could further enhance the infiltration of CD4 + T cells and achieve a synergistic therapeutic effect on tumor. Therefore, our study demonstrates that the modulation of AICD of tumor-infiltrating CD4 + T cells using HDACIs can enhance anti-tumor immune responses, uncovering a novel mechanism underlying the anti-tumor effect of HDACIs.
INTRODUCTION
Tumors are composed of many different cell types, among which immune cells are claimed to play a critical role in controlling tumor growth. 1 During tumor development, immune cells, especially tumor-infiltrating T lymphocytes (TILs), secrete an array of cytokines that can kill tumor cells directly. 2 Owing to the important role of immune system in eliminating potential tumor cells, immunotherapy is considered as a very promising strategy for treating tumors. For instance, the adoptive transfer of TILs has been shown to dramatically enhance tumor rejection in some settings. 3, 4 Furthermore, antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been shown to be very effective in treating cancers, a result of enhanced anti-tumor immunity by TILs. [5] [6] [7] However, tumor cells are not always successfully eliminated by immune responses. One mechanism is that even as T cells continually migrate into tumor sites, they often undergo apoptosis prior to being able to carry out their anti-tumor functions. 8 Among the mechanisms underlying T-cell apoptosis, activation-induced cell death (AICD) is very important as a normal control mechanism for immune response. AICD was first described in 1989 and is considered critical for regulating T-cell viability and immune homeostasis. 9 We have shown that activated CD4 + T cells undergo AICD upon re-stimulation. Re-stimulation rapidly induces FasL (CD95L) expression, and FasL-Fas interaction triggers the caspase cascade, leading to T-cell apoptosis. 9, 10 Importantly, the impairment of FasL-Fas pathway in humans affects lymphocyte apoptosis and leads to the autoimmune lymphoproliferative syndrome, which is characterized by the accumulation of activated lymphocytes and autoimmune disease. 11 Owing to this important role of FasL-mediated AICD in controlling immune response, the possibility of regulating AICD for improved cancer immunotherapy requires further exploration.
Histone deacetylase inhibitors (HDACIs) are small molecules that inhibit the activity of histone deacetylases (HDACs). In recent years, HDACIs have entered the clinic as anti-tumor drugs. Vorinostat, a synthetic compound that is structurally similar to the first-described natural HDACI, trichostatin A (TSA), was the first FDA-approved HDAC inhibitor for the treatment of relapsed and refractory cutaneous T-cell lymphoma. Many other HDACIs are currently in clinical trials, either as mono-therapies or in combination with conventional chemotherapy. [12] [13] [14] Still, the mechanisms underlying their therapeutic effects remain elusive. 15 Interestingly, substantial evidence has shown that HDACIs can induce apoptosis in a variety of cell types through different mechanisms. 16, 17 The role of HDACIs in AICD is unclear, however, and whether this role contributes to their potential utility in tumor therapy remains to be determined.
In this study, we employed TSA, and found that it significantly suppressed the growth of B16F0 melanoma through inhibiting apoptosis of activated CD4 + T lymphocytes within tumor. Furthermore, this effect of TSA was exerted through specifically downregulating FasL expression on infiltrating CD4 + T cells, which resulted in enhanced anti-tumor immune response. This role of FasL was further evidenced by the fact that TSA provided no benefit in the treatment of tumor-bearing gld/gld mice. Importantly, we found that TSA and CTLA4 antibody acted synergistically to greatly enhance CD4 + T-cell infiltration, and together may offer better tumor therapeutic effects than either agent alone. Our findings reveal a novel mechanism underlying the anti-tumor effect of HDACIs, which is inhibiting AICD of tumor-infiltrating CD4 + T lymphocytes.
RESULTS
TSA inhibits tumor growth by promoting the survival of infiltrating CD4 + T cells
As tumor-infiltrating lymphocytes (TILs) are essential in eliminating tumor cells, we wondered whether HDACIs exert their therapeutic effect through TILs. We tested this possibility in the B16F0 melanoma model established on both C57BL/6 mice and nude mice. To determine the optimal concentration of TSA, two doses of TSA were administrated; 1 μM/kg (referred to as 'low dose') and 3 μM/kg, the concentration widely used for experimental tumor treatment (referred to as 'high dose'). 18 We found that in C57BL/6 mice, regardless of concentration, TSA administration resulted in significantly smaller tumors compared with vehicle alone (Figure 1a) . Surprisingly, when similar studies were conducted in nude mice, which lack a thymus and therefore have no T cells, the therapeutic effect of low-dose TSA was completely absent whereas the effect of high-dose TSA remained (Figure 1b ). This suggested that the anti-tumor effect of low-dose TSA was exerted through the immune system, most likely through T cells; whereas that of high-dose TSA was independent of T-cell immunity, possibly by directly inducing tumor cell death as previously reported. 18 To test these possibilities, we first employed Rag1 −/− mice, which have no T lymphocytes. As expected, there was no anti-tumor effect at low-dose TSA ( Figure 1c) . Next, we stimulated B16F0 cells with different concentrations of TSA in vitro and found as high as 200 nM TSA could indeed induce tumor cell death (Supplementary Figure 1) . As lower TSA concentrations should induce fewer side effects and be less toxic, we adopted 1 μM/kg TSA for the subsequent experiments.
To identify which subset of T cells is essential for the anti-tumor effect of TSA, we employed CIITA −/− mice that have no CD4 + T cells, and β2m − / − mice that lack CD8 + T cells. Interestingly, without CD4 + T cells, low-dose TSA had no effect; in the absence of CD8 + T cells, however, TSA did exert significant therapeutic effect (Figure 1d) . Therefore, CD4 + T cells are indispensable for the anti-tumor effect of TSA.
Owing to the important role of CD4 + T cells, we next explored the infiltration of activated CD4 + T lymphocytes within the tumor microenvironment in wild-type mice. Interestingly, TSA administration resulted in significant increases in the fraction of CD4 + CD62L
− activated T cells in tumor tissue (Figure 1e ). Besides, histological analysis also showed elevated infiltration of T cells in tumor (Supplementary Figure 2) . Most of these cells were also positive for CD44, which is an indicative marker for effector memory T cells (Supplementary Figure 3) . More importantly, the absolute number of these cells per gram of tumor also increased ( Figure 1f ). We further isolated CD4 + CD62L
− cells from tumor and tested the expression of cytokines associated with T cell activation, including interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and granulocyte-macrophage colony stimulating factor (GM-CSF). We found that TSA could significantly increase the expression of these cytokines (Figure 1g ). Elevated serum levels of these cytokines were also detected (Supplementary Figure 4) . Taken together, TSA administration results in increased CD4 + T cells within tumor tissue, which leads to enhanced antitumor immune responses and constrained tumor growth.
To further explore the reasons responsible for the increased activated CD4 + T cells, we examined the apoptotic status of these cells within tumor. Interestingly, we found that the TSA treatment dramatically reduced CD4 + T cell death, as revealed by their permeability to 7-AAD (Figure 1h ). Therefore, TSA administration increased the number of activated CD4 + T cells within the tumor possibly through inhibiting apoptosis.
HDAC inhibition promotes the survival of T-cell hybridoma by blocking AICD As we demonstrated, TILs undergo decreased apoptosis in response to TSA treatment. As AICD is one of the major mechanisms underlying the apoptosis of TILs, we hypothesize that this is through the inhibition of AICD happening in tumor microenvironment. To this end, we examined the effect of HDAC inhibition on AICD in vitro. We employed A1.1 cells, a T-cell hybridoma that is well established for the investigation of AICD in T lymphocytes. 19 AICD of A1.1 cells was induced by TCR ligation using immobilized anti-CD3. The addition of TSA at doses of 50-100 nM resulted in a striking reduction in AICD (Figures 2a and b) , a sharp contrast to previous reports of the pro-apoptotic role of TSA. 16 TSA alone showed no effect on the survival of A1.1 cells (Supplementary Figure 5) . Furthermore, the inhibitory effect of TSA was apparent soon after re-activation ( Figure 2c ). To corroborate these findings, we employed another HDACI, sodium butyrate (NaBu), and observed similar results (Supplementary Figure 6) . To confirm that cell death was indeed reduced by TSA treatment, we measured cell viability using CCK-8 and found a nearly complete reversal of cell death by TSA (Figure 2d ). Therefore, inhibition of HDAC activity using HDACIs can protect T cells from AICD and thereby greatly promote their survival.
HDACIs suppress TCR-initiated FasL expression in T-cell hybridoma TILs may be susceptible to other types of apoptosis besides AICD; therefore, we next examined the effect of TSA on apoptosis induced by other stimuli. A1.1 cells were exposed to actinomycin D (ActD), hydrogen peroxide (H 2 O 2 ) or UV irradiation, which are all reported to induce tumor cell death, each through a different mechanism. 20, 21 Interestingly, following these cellular insults, TSA treatment did not reduce the proportion of apoptotic cells in A1.1 cell cultures (Figure 3a) . Moreover, TSA could not inhibit A1.1 cell death induced by serum deprivation. Thus, TSA could not block growth factor withdrawal-induced T-cell death, one of the mechanisms underlying T-cell death within the tumor microenvironment 22, 23 (Figure 3b ). Also, levels of Bim, the molecule mediating growth factor withdrawal-induced T-cell death, were unaffected in the presence of TSA (Figure 3c ). Therefore, the inhibitory effect of TSA is specific to AICD.
It has been shown in A1.1 cells that TCR re-stimulation induces FasL expression, leading to Fas ligation and resultant apoptosis. 10, 24 To this end, we next examined the effects of TSA on FasL expression. We found that TSA completely blocked FasL upregulation at both mRNA and protein levels (Figures 3b and c) . Similarly, NaBu was also found to inhibit FasL expression (Supplementary Figure 7) . When CD90 (Thy-1) antibody was used to activate A1.1 cells, we again found that TSA completely inhibited subsequent FasL expression and apoptosis (Supplementary Figure 8) , providing further evidence that HDACIs exert their anti-apoptotic effect by preventing FasL upregulation. In contrast, Fas expression was not suppressed by HDACIs; instead, HDACIs enhanced Fas in a dose-dependent manner (Figure 3d ). To further verify the role of FasL in the inhibitory effect of TSA on AICD, we next employed the FasL mimic Jo2. As expected, TSA did not inhibit Jo2-induced cell death (Figure 3e ), indicating that the Fas response is unimpeded by TSA; rather, it is the lack of FasL that prevents AICD. Interestingly, we found that in the presence of Jo2, a Fas-activating antibody, TSA dramatically increased the apoptotic rate of A1.1 cells, a finding which may be explained by the elevated level of Fas expression observed following TSA treatment. These results demonstrate that HDACIs inhibit FasL expression by activated A1.1cells, which, despite the increased Fas expression, leads to complete inhibition of AICD. + CD62L − cells were also stained for 7-AAD. The extent of apoptosis by activated CD4 + T cells was determined by the percentage of 7-AAD + , as shown. Statistical analysis was performed using the Student's t-test. *P o 0.05, **P o 0.01; ns, not significant. whereas TSA alone showed no effect (Supplementary Figure 9) , similar to the T-cell hybridoma results. Significant inhibition occurred at a dose as low as 10 nM and complete inhibition required only 25 nM TSA. Furthermore, during AICD, FasL and Fas were regulated by TSA much as they were in A1.1 cells (Figures 4c  and d) . Thus, TSA similarly inhibits AICD in both primary CD4 + T cells and A1.1 hybridoma cells through the regulation of FasL expression.
TSA inhibits FasL expression by regulating NFAT1 and Egr2
It is well known that TCR activation triggers two separate pathways, calcium/nuclear factor of activated T cells (NFAT) signaling and PKC signaling. 25 It has been proposed that NFAT1 (NFATp, NFATc2) and PKC are both required for the expression of FasL, whereas Fas expression needs only PKC. [26] [27] [28] As TSA specifically inhibits FasL but not Fas, we examined the activity of the key molecule, NFAT1. Cytoplasmic and nuclear exacts were prepared from anti-CD3 re-activated A1.1 cells to examine the distribution of NFAT1. We found that with high concentrations of TSA, nucleus-associated NFAT1 was decreased, but not p53 or p65, which both regulate Fas expression during AICD 29, 30 ( Figure 5a,  Supplementary Figure 10 ). These findings indicate that the inhibitory effect of TSA on FasL expression is closely related to the specific suppression of NFAT1 activity.
It has been reported that NFAT1 translocation induces expression of early growth factor 2 and 3 (Egr2/3), which would directly bind to the FasL promoter and launch FasL expression. 28 Accordingly, to verify the effect of TSA on NFAT1 translocation, we next examined Egr2/3 expression. We found that TSA inhibited the expression of NFAT-induced Egr2, but not Egr3, indicating that Egr2 rather than Egr3 is the critical regulator of FasL in A1.1 cells (Figure 5b ). Taken together, these results demonstrate that TSA exerts its effect on transcription factors that are known to regulate FasL expression.
TSA inhibits apoptosis of CD4 + T cells in tumors by suppressing FasL expression
We have demonstrated in vitro that the anti-apoptotic effects of HDACIs result from inhibition of FasL expression. To determine whether this effect is responsible for decreased apoptosis of CD4 + T cells following TSA administration in vivo, we specifically examined FasL expression by tumor-infiltrating CD4 + T cells, and found that TSA treatment dramatically reduced the expression of FasL on these cells (Figure 6a ). This shows that TSA indeed inhibits the FasL-mediated AICD of tumor-infiltrating CD4 + T cells in vivo. To further verify that this phenomenon was responsible for the therapeutic effect of TSA, we again utilized the B16F0 melanoma model and compared the effects of TSA on resultant tumor mass in both wild-type and gld/gld mice, in which FasL is mutated. We found that the therapeutic effect of TSA that was apparent in the wild-type mice and was completely absent in gld/gld mice (Figure 6b) . Similarly, in gld/gld mice, TSA did not increase the number or percentage of CD4 + T cells in the tumor, or the serum level of T-cell cytokines (Figures 6c and e) . Furthermore, the AICD of CD4 + T cells was unaffected by TSA in gld/gld mice (Figure 6f) . Thus, the inhibition of FasL-mediated AICD by TSA is crucial for its ability to boost the numbers of infiltrating T lymphocytes. This conclusion was further supported by the finding that the lack of FasL in gld/gld mice also led to greater numbers of tumor-infiltrating T cells and smaller tumors, as compared with wild-type mice.
To test whether this phenomenon can be generalized to other tumor types, we employed EL4 lymphoma model and obtained results similar to those with melanoma: EL4 lymphoma growth was suppressed by TSA administration, and infiltration by CD4 + T lymphocytes was enhanced in wild-type mice, but not in gld/gld mice (Supplementary Figure 11) .
The combined administration of TSA and CTLA4 antibody achieves better anti-tumor effect It has been reported that HDACIs have a much stronger therapeutic effect when combined with other anti-tumor agents. 31 CTLA4 antibody has been shown to be effective in the treatment of several types of cancers, especially melanoma, owing to its ability to enhance the T-lymphocyte response. 32 Therefore, we reasoned that combining TSA and anti-CTLA4 might have a synergistic therapeutic effect. To test this, anti-CTLA4 was coadministered with TSA in the B16 melanoma model. As expected, the combination of these two agents prolonged the survival of tumor-bearing mice to a much greater extent than did either alone (Figure 7a ). Co-administration of TSA and anti-CTLA4 also showed a stronger anti-tumor effect, limiting melanoma growth more than TSA or anti-CTLA4 alone (Figure 7b) . Furthermore, although the percentage of activated CD4 + CD62L − T lymphocytes in the tumors was no greater with the combined treatment, the absolute number of these cells was strikingly increased compared with either treatment alone (Figure 7c and d) . Taken together, these results demonstrate that TSA and CTLA4 antibody can act synergistically to increase the number of activated CD4 + T lymphocytes, compared with either alone, resulting in a more potent therapeutic effect on melanoma growth. This finding has great potential to guide the clinical application of HDACIs in the treatment of cancer.
DISCUSSION
For the past two decades, a large number of HDAC inhibitors have been purified from natural sources, and others have been synthesized. 12 In recent years, accumulating evidence has demonstrated that HDACIs have promising therapeutic potential for the treatment of various tumors. [12] [13] [14] At least two such agents (Vorinostat and Romidepsin) have been approved by the FDA, and many others are under clinical trial. 33 Still, the mechanisms underlying the therapeutic effects of HDACIs remain elusive.
There is substantial evidence that tumor cells can induce FasFasL-mediated apoptosis of TILs as a way to escape immune surveillance. 2, 8 In fact, the restoration of TIL function within tumor by inhibition of apoptosis has been adopted as a therapeutic strategy and found to dramatically improve tumor rejection. 3, 34 Therefore, the apoptotic status of TILs is closely related to tumor growth and might be associated with the anti-tumor effect of HDACIs. TILs are susceptible to several types of apoptosis, among which AICD is the major mechanism regulating the viability of activated T cells, which are the main effectors in anti-tumor immune responses. Additionally, AICD is also mainly mediated through the Fas-FasL pathway. 9, 10, 24 For these reasons, we focused on the effect of HDACIs on the AICD of activated T lymphocytes in tumors. In our studies, we have shown that HDACIs can inhibit the apoptosis of activated T cells. In recent years, however, there has arisen substantial evidence suggesting that HDACIs can themselves induce T-cell death. 35, 36 These reports are inconsistent with our findings. We noticed, however, that the infiltrating cells responsible for attacking tumors are mostly activated functional T cells, and little has been reported about the effect of HDACIs on activated T cells. To our knowledge, our current study is the first to report that HDACIs have an anti-apoptotic effect on activated T lymphocytes. Furthermore, our studies suggested that the antiapoptotic effects of HDACIs on the activated T cells were observed at lower concentrations of the drug, whereas we also observed direct induction of tumor cell apoptosis at higher levels. It is possible that both the activation state of the CD4 + T cells, as well as the dose of HDACI used may determine whether HDACIs exert pro-or anti-apoptotic effects in T cells.
We have demonstrated the anti-apoptotic effect of HDACIs on tumor-infiltrating CD4 + T cells resulted from inhibition FasL expression following re-activation. The Fas-FasL interaction is known to mediate the AICD of Th1 cells, whereas the major regulator of AICD of Th2 cells is granzyme B. 37, 38 We found that granzyme B expression on TILs was not changed by TSA treatment like FasL (data not shown), suggesting that TSA may preferentially suppress AICD in Th1 CD4 + cells. Interestingly, increased numbers of activated Th1 cells are reported to be associated with prolonged disease-free survival in various tumor models and human cancers; whereas Th2 cells are associated with cancer progression and metastasis. [39] [40] [41] Therefore, it is possible that the Statistical analysis was performed using the Student's t-test. *P o0.05, **P o0.01; ns, not significant.
anti-tumor effect of HDACIs may be due to inhibition of FasLmediated apoptosis of Th1 cells, but this hypothesis remains to be further tested.
HDACIs inhibit the activity of multiple HDACs. Among the 11 classical HDACs, nearly half of them have been reported to regulate cell death. Inhibition of either HDAC1 or HDAC2 was reported to be associated with increased apoptosis in human cancer cells. 42 Also, an HDAC8-specific inhibitor was shown to selectively induce apoptosis in T-cell-derived lymphoma and leukemic cells, but not in solid cancer cell lines. 42 On the other hand, Bolger et al. 43 claimed that inhibition of HDAC4 could suppress cell death. Especially, HDAC7 was reported to be exported to the cytoplasm of T cells after TCR activation and mutation in HDAC7 inhibits its nucleocytoplasmic shuttling and suppresses TCR-induced apoptosis. 44 Owing to the strong similarity between HDAC7 and FasL in both expression pattern and functional effects on T-cell apoptosis, we considered that HDAC7 may be a candidate FasL regulator. In fact, we examined the expression of HDAC7 in A1.1 cells during AICD induction and found that it was upregulated by anti-CD3 ligation and suppressed by HDACI treatment, much as was FasL expression, further indicating a possible relationship between HDAC7 and FasL (data not shown). However, the specific HDACs responsible for the regulation of FasL remain obscure and need to be identified.
In our study, we have shown that the inhibitory effect of TSA on FasL expression is related to decreased NFAT activity. Such inhibition can result in the suppression of AICD of T cells. As a well-known NFAT inhibitor, cyclosporin A (CsA) can suppress T-cell activation 45 and FasL expression during AICD. 9 CsA has been widely used as an immunosuppressant for the treatment of rheumatoid arthritis or inflammation induced by organ transplantation. 46, 47 Moreover, its application can promote tumor growth by suppressing the overall immune surveillance by T cells. 48 The differences between TSA-and CsA-mediated effects on tumors most likely can be attributed to their different regulatory effects on T cells. Unlike CsA, when TSA inhibits the progression of AICD, it shows no inhibitory effect on the proliferation of T cells by the same concentration (data not shown). Our results suggest that this regulation is the potential mechanism mediating tumor inhibition by TSA. Compared with TSA, in addition to its wellknown suppression on T cells, CsA is also known to regulate cancer progression via promoting transforming growth factor beta (TGFβ), through a mechanism independent of host immunity. 49 Therefore, the mechanism underlying the different effects of CsA and TSA on tumor growth needs further exploration.
Our studies have proven that FasL inhibition results in increased numbers of tumor-infiltrating T cells, which is the basis of the antitumor effect of TSA. FasL expression by tumor cells is also one of the mechanisms underlying the death of tumor-infiltrating lymphocytes. 8 However, we found that the expression of FasL on B16F0 cells is very low and TSA shows no inhibitory effect on its expression (data not shown). In 2002, it was reported that the main anti-tumor mechanism of TSA was Fas ligation-induced tumor cell death. 18 If that were the case, however, then tumor mass in our gld/gld mice would be expected to be even greater than that in wild-type mice, as gld/gld mice should have less tumor cell death. Instead, our studies show that tumor growth was suppressed in gld/gld mice compared with wild-type mice, a result that we attribute to the elevated numbers of infiltrating T cells. Of note, Maecker et al. 18 inoculated with MEF cells rather than melanoma cells to induce murine tumors, and it might be possible that TSA exerts its anti-tumor effect through different mechanisms in different types of tumors. Furthermore, the concentration of TSA Maecker et al. used was around 3 μM/kg, whereas in our experiment, we employed much less concentration to 1 μM/kg. We have already shown that high-dose TSA could indeed induce tumor cell death, which is consistent with their results. Overall, we believe the anti-tumor effect of HDACIs is due, at least in part, to enhanced T lymphocyte survival within tumor. Nevertheless, the details of the mechanism need to be further investigated.
In conclusion, the results presented here support the following scenario: HDAC inhibitors suppress the apoptosis of activated T lymphocytes by inhibiting their expression of FasL, thus enhancing their survival. This leads to increased numbers of activated T cells within tumor, thereby enhancing anti-tumor immunity and constraining tumor growth. Thus, we have proposed a new mechanism by which HDACIs exert their therapeutic effects in cancer. With further study and a more complete understanding of how HDACIs regulate T lymphocyte survival, the use of HDACIs can be exploited for broader and more effective cancer therapy.
MATERIALS AND METHODS Animals
C57BL/6 and nude mice were purchased from the Shanghai Laboratory Animal Center of Chinese Academy of Sciences, Shanghai, China, and maintained under specific pathogen-free conditions. Rag1 − / − mice, gld/ gld mice, CIITA − / − mice and β2m − / − mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed in the Vivarium of Shanghai Jiao Tong University School of Medicine. All procedures were approved by the Institutional Animal Care and Use Committee of the Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences. Animals were matched for age and gender in each experiment.
Antibodies and reagents TSA, sodium butyrate, propidium iodide, actinomycin D and dimethyl sulfoxide were from Sigma-Aldrich (St Louis, MO, USA). Mouse CD90 (Thy-1) functional grade purified antibody, recombinant mouse IL-2, anti-mouse CD3 FITC, anti-mouse CD4 PerCP-Cyanine 5.5, anti-mouse CD4 PE, antimouse CD62L APC, anti-7-AAD PerCP-Cyanine5.5 and anti-mouse CD95 (Fas) PE were from eBiosciences (La Jolla, CA, USA). Anti-CD95 (Jo2) was from BD Pharmingen (San Diego, CA, USA). Mouse CD3 and CD28 polyclonal antibodies were from Abcam (Cambridge, MA, USA). Anti-CTLA4 was generated as described previously. 50 Hydrogen peroxide (30%) was from Sinopharm Chemical Reagent (Shanghai, China). SCIENTZ 03-II UV crosslinker was from Scientz Biotechnology (Ningbo, China).
Cells
A1.1 T cell hybridomas were maintained as previously described.
19 CD4 + T cell blasts were generated as follows. Naïve splenocytes (1 × 10 6 cells/ml) were cultured on plastic-bound anti-CD3 and soluble anti-CD28 for 48 h. These cells were harvested, and CD4 + T cells were isolated by mouse CD4 + T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), and then cultured with IL-2 (200 U/ml, R&D, Minneapolis, MN, USA) alone for 48 h. All cells were cultured in RPMI-1640 medium supplemented with 10% heatinactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 50 mM β-ME (all from Invitrogen, Carlsbad, CA, USA). B16F0 mouse melanoma cells and EL4 lymphoma cells were cultured in DMEM medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
AICD induction A1.1 T cell hybridoma cells or CD4 + T cell blasts (1 × 10 6 cells/ml) were activated on plastic-bound anti-CD3 in 12-well plates for various times. Cell viability following AICD induction was determined by culture with the prescribed reagent in the Cell Counting Kit-8 (Beyotime Biotechnology, Shanghai, China) for 2 h following the manufacturer's instructions, and the optical density at 450 nm was measured for the supernatant.
Flow cytometric analysis
Cells were suspended at a concentration of 2 × 10 6 cells/ml (in phosphatebuffered saline with 2% FBS) and 200 μl of suspension was incubated with propidium iodide staining buffer (0.1 mg/ml propidium iodide, 0.1% saponin in phosphate-buffered saline) or fluorescently labeled antibodies for 30 min. Antibody-stained cells were washed twice with phosphatebuffered saline. Fluorescence intensity was measured by flow cytometry (BD FACSCalibur, BD Bioscience, Shanghai, China).
Real-time PCR
Total RNA was isolated using RNAprep pure Cell/Bacteria Kit (Tiangen biotech, Beijing, China). First-strand cDNA synthesis was performed using PrimeScript RT Master Mix (TaKaRa Biotech, Dalian, China). The levels of mRNA of genes of interest were measured by real-time PCR (7900 HT by Applied Biosystems, Foster City, CA, USA) using SYBR Green Master Mix (TaKaRa Biotech). Total amount of mRNA was normalized to endogenous β-actin mRNA. Sequences of PCR primer pairs were as follows: mouse FasL, forward 5′-TCCGTGAGTTCACCAACCAAA-3′ and reverse 5′-GGGGGT TCCCTGTTAAATGGG-3′; mouse Egr2, forward 5′-GCCAAGGCCGTAGACAAA ATC-3′ and reverse 5′-CCACTCCGTTCATCTGGTCA-3′; mouse Egr3, forward 5′-CCGGTGACCATGAGCAGTTT-3′ and reverse 5′-TAATGGGCTACCGAG TCGCT-3′; mouse IL-2, forward 5′-GTGCTCCTTGTCAACAGCG-3′ and reverse 5′-GGGGAGTTTCAGGTTCCTGTA-3′; mouse GM-CSF, forward 5′-GGCCTTG GAAGCATGTAGAGG-3′ and reverse 5′-GGAGAACTCGTTAGAGACGACTT-3′; mouse IFNγ, forward 5′-ATGAACGCTACACACTGCATC-3′ and reverse 5′-CCATCCTTTTGCCAGTTCCTC-3′; mouse TNFα, forward 5′-GACGTGGA ACTGGCAGAAGAG-3′ and reverse 5′-TTGGTGGTTTGTGAGTGTGAG-3′; mouse β-actin, forward 5′-CCACGAGCGGTTCCGATG-3′ and reverse 5′-GCCACAGGATTCCATACCCA-3′;
Mouse tumor model For the melanoma model, each mouse was injected with 0.4 × 10 6 B16F0 in 100 ml phosphate-buffered saline intramuscularly on the left thigh on day 1. In the TSA dosing experiment, 1 μM/kg or 3 μM/kg TSA was administrated intraperitoneally to C57BL/6 or nude mice every other day starting on day 6, with dimethyl sulfoxide serving as a vehicle control. In other experiments, melanoma was established as described and 1 μM/kg TSA was administrated with or without 200 μg/ml anti-CTLA4 antibodies. Mice were observed daily and killed when tumor began to significantly affect mobility or 41000 mm 3 . Cytokine levels in serum were determined by multiplexed bead immunoassay using the Luminex Technology (Bio-Plex, Bio-Rad Laboratories, Hercules, CA, USA). The melanoma tumors were excised and weighed and mechanically minced, then separated by discontinuous density gradient centrifugation. Briefly, cells were pelleted, resuspended in 70% Percoll (GE healthcare, Piscataway, NJ, USA), overlaid with 30% Percoll, and then centrifuged at 2000 r.p.m. for 20 min at room temperature. Lymphocytes were aspirated from the interface and washed twice with medium. CD4 + CD62L − lymphocytes were isolated by mouse CD4 + CD62L − T cell isolation kit (Miltenyi) according to the manufacturer's instructions. Four micrometer paraffin sections were prepared and stained with indicated antibody according to the protocol provided by the manufacturer. For the EL4 lymphoma model, the cells and TSA were injected as in the B16 model. The resultant tumors were excised and weighed, and digested by type I collagenase (0.5 mg/ml) at 37°C for 2 h, and lymphocytes were then isolated by Percoll gradient.
Western blotting analysis
For the detection of Bim and P-65 protein, nuclear or cytoplasmic proteins were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. Samples were heated in sodium dodecyl sulfate sample buffer at 95°C for 10 min, separated on a polyacrylamide gel, and separated proteins were electroblotted onto polyvinylidene difluoride membranes. Specific proteins were revealed by mouse and rabbit antibodies against NFAT1, p53, laminB or GAPDH (Cell Signaling Technology, Danvers, MA, USA) by overnight incubation at 4°C, followed by chemiluminescent detection according to the manufacturer's instructions.
Statistical analysis
Data are presented as mean ± s.e.m. Statistical significance was assessed using unpaired two-tailed Student's t-test, *Po 0.05, **P o0.01, or Log-Rank test in survival experiment: **Po0.01, ***Po 0.001.
